Novartis announces results on rPFS improvements across subgroups with Pluvicto
Novartis (NVS) announced results showing consistent radiographic progression-free survival, rPFS, improvement across key subgroups with Pluvicto plus standard…
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Novartis Pharma AG Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto…